Camurus ABCAMRF -3.57%79 EV-to-FCF is 34.40 as of Jun. 24, 2026. GuruFocus rates CAMRF with a GF Score™ of 79/100 and a GF Value™ of $83.14 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 328 Biotechnology companies, Camurus AB ranks worse than 68.6% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Camurus AB's Enterprise Value is $2,959.0 Mil.
Camurus AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $86.0 Mil. Therefore, Camurus AB's EV-to-FCF for today is 34.40.
The historical rank and industry rank for Camurus AB's EV-to-FCF or its related term are showing as below:
CAMRF'
s EV-to-FCF Range Over the Past 10 Years
Min: -320.3 Med: -12.05 Max: 1088.61
Current: 33.48
During the past 13 years, the highest EV-to-FCF of Camurus AB was 1088.61. The lowest was -320.30. And the median was -12.05.
CAMRF's EV-to-FCF is ranked worse than 68.6% of 328
companies
in the Biotechnology industry
Industry Median: 14.86
vs CAMRF: 33.48
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Camurus AB's share price for today is $54.00.
Camurus AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.205.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Camurus AB EV-to-FCF Related Terms
Camurus AB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Camurus AB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Camurus AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Camurus AB's EV-to-FCF falls into.
Camurus AB's current Enterprise Value is $2,959.0 Mil.
Camurus AB's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $86.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a EV-to-FCF of 34.40 as of Jun. 24, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Camurus AB and its competitors. According to the industry distribution chart, Camurus AB ranks #225 out of 328 companies in the Biotechnology industry, placing it in the top 68.6%.
Is Camurus AB's EV-to-FCF too high?
Camurus AB's current EV-to-FCF is 34.40. The Biotechnology industry median EV-to-FCF is 14.86. Camurus AB's value of 34.40 is 131.5% above this industry median. Based on the distribution chart, Camurus AB ranks #225 out of 328 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Camurus AB has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #225 out of 328 companies for EV-to-FCF. This places Camurus AB in the lower half of its industry. The industry median EV-to-FCF is 14.86. Camurus AB's value of 34.40 is 131.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.86, based on 328 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current EV-to-FCF of 34.40 is 131.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current EV-to-FCF is 34.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $83.14, compared to a current price of $54.00 — trading 35% below its estimated fair value. The current EV-to-FCF is 34.40 and 131.5% above the Biotechnology industry median of 14.86. Camurus AB's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Camurus AB (CAMRF), the current EV-to-FCF is 34.40 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $54.00 is trading 35% below its estimated GF Value™ of $83.14.
GuruFocus considers Camurus AB to be Significantly Undervalued.
Key valuation signals for CAMRF:
EV-to-FCF: 34.40
GF Value™: $83.14 vs. price of $54.00 (35% below fair value)
Industry Position: 131.5% above the Biotechnology median (#225 of 328)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
79GF Score
Get the complete analysis for CAMRF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
